The backend infrastructure built by compound pharmacies to serve telehealth giants like Hims and Ro is now mature. This creates an opportunity for new brands to quickly launch and ship prescription products, effectively using these pharmacies as a platform for regulated health and wellness DTC.

The high cost of insulin isn't from manufacturing but from the complex distribution chain of wholesalers, pharmacies, and insurers. Project Insulin's core strategy is to bypass this system entirely with a direct-to-patient mail-order pharmacy model, effectively eliminating the middlemen who inflate the final price.

The US healthcare system rewards inefficiency, with multiple parties adding costs. Cash-pay systems bypass this, offering services and drugs at a lower net price by avoiding negotiations and markups inherent in the insurance-based model.

The rise of cash-pay proactive health creates a two-tier system. One group can afford to defect from insurance and build their own health stack, while another cycles through the traditional system, relying on charity care, exacerbating inequity.

The idea of a single, equitable healthcare system is often a myth. Regardless of the official structure, a cash-pay system for faster or better care will almost always emerge for those who can afford it, a reality policymakers must acknowledge.

A surprising driver of the burgeoning global obesity drug market, projected to hit $20 billion outside the U.S., is that it's almost entirely cash-pay. Consumers in countries like the UK are willing to spend hundreds of dollars per month out-of-pocket, demonstrating strong demand independent of traditional reimbursement systems.

Direct-to-consumer telehealth companies like Hims achieve rapid growth via a vertically integrated model of marketing, medical groups, and pharmacies. This structure allows them to generate revenue from selling medicines, a more scalable business than relying on fees from the practice of medicine alone.

Four key variables determine a drug's suitability for a direct-to-consumer (DTC) channel: it must be self-administered, the condition must be diagnosable via telehealth without in-person confirmation, it should have a lower price point, and be free of restrictive FDA regulations.

The shift to high-deductible plans forced consumers to directly feel the financial burden of healthcare. This created a new willingness to pay out-of-pocket for disruptively priced, superior consumer health services, effectively establishing a viable direct-to-consumer (DTC) market that investors previously dismissed.